Abstract
In this work we analysed the characteristics of the cell-permeable peptide TAT-PTD fused to cystatin B (CSTB) to evaluate its potential for protein therapy of Unverricht-Lundborg (UL) epilepsy. TAT-PTD-CSTB does not penetrate the cells despite initial evidence of time and concentration-dependent transduction. Therefore, it cannot be used as a form of replacement of the intracytoplasmic protein missing in UL. Importantly, we discuss precautions to avoid false-positive results when working with TAT-PTD for protein therapy of neurological diseases.
Original language | English (US) |
---|---|
Pages (from-to) | 75-79 |
Number of pages | 5 |
Journal | Epilepsy Research |
Volume | 72 |
Issue number | 1 |
DOIs | |
State | Published - Nov 2006 |
Keywords
- Blood-brain-barrier
- Cell-permeable peptide
- Progressive myoclonus epilepsy
- Protein therapy
- TAT-PTD
- Unverrricht-Lundborg
ASJC Scopus subject areas
- Neurology
- Clinical Neurology